Vis børsmeldingen
license option by 3 months, otherwise the agreement remains unchanged
Oslo, Norway 6 January 2021 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing immune activators to target hard-to-treat solid
tumors, today announces that it has granted an extension of 3 months to the
exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for
clinical development and licensing of the Targovax mutant RAS vaccines TG01 and
TG02 in China, Hong Kong, Macau and Singapore.
On 8 January 2020 Targovax and IOVaxis announced that they had entered into an
exclusive option agreement with 12-month validity for the development and
commercialization of Targovax´s TG vaccines in Greater China and Singapore (see
press release here (https://www.targovax.com/en/targovax-and-iovaxis
-therapeutics-enters-option-agreement-for-tg-mutant-ras-vaccine-license-and
-clinical-development-in-china/)). An IND application to initiate clinical
development of TG01 has been submitted to the Chinese National Medical Products
Administration (NMPA), but the application preparation and regulatory review
process has been delayed due to COVID-19 related issues. To accommodate the
delay caused by these unforeseen circumstances, Targovax has granted to IOVaxis
an extension to the license option period by 3 months. Otherwise, the option
agreement remains unchanged and in force.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients with targeted
therapeutic cancer immunotherapies. The Group’s pipeline aims at different
cancer indications, including melanoma, mesothelioma and colorectal cancer. The
products are designed to harness the patient’s own immune system to fight the
cancer, whilst also delivering a favorable safety and tolerability profile.
Further, the products are well positioned for combinations with other treatment
approaches, including other immunotherapies, surgery, radiation and
chemotherapy.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. ONCOS-102 is currently
being tested in mesothelioma, melanoma and colorectal cancer and has already
shown promising clinical results both as monotherapy and in combination with
chemotherapy, and a checkpoint inhibitor.
Kilde